CANF vs UNH

Can-Fite BioPharma Ltd. remains an extremely high-risk, deeply speculative investment, with a very low probability of achieving 10x growth within 3-5 years. While FY2025 financials show declining revenue and worsening net loss, recent material positive catalysts warrant a slight score increase. These include an improved short-term cash position (+$4.3M in March 2026, totaling ~$12.84M), significan...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...